CD274 and neoplasm: Many predictive biomarkers for response to ICI have been proposed, such as PD-L1, which was validated based on KEYNOTE 010 [47] and is used in clinical practice, and tumour mutational burden (TMB) [54, 55] which has been studied widely but is not yet validated; however, these biomarkers are limited by issues related to interpretation.